Search results for "Marker"

showing 10 items of 3799 documents

High-sensitivity Cardiac Troponin for the Evaluation of Patients With Suspected ACS: A True or a False Friend?

2019

medicine.medical_specialtyCardiac troponinbusiness.industryGeneral MedicineTroponinDiagnosis DifferentialInternal medicinemedicineCardiologyHumansAcute Coronary SyndromebusinessSensitivity (electronics)AlgorithmsBiomarkersRevista Española de Cardiología (English Edition)
researchProduct

Routine cardiac troponin assessment after percutaneous coronary intervention

2019

: Although the angiographic and procedural success of percutaneous coronary intervention (PCI) is now very high, some severe complications may still develop, including periprocedural myocardial infarction (MI). An accurate diagnosis of this condition is essential for guiding the clinical management, as these patients may need a tailored management. The current recommendations for diagnosing periprocedural myocardial infarction based on the fourth universal definition appear at first sight straightforward, but the clinical and prognostic significance of routine periprocedural cardiac troponin (cTn) assessment remains uncertain. The current scientific evidence suggests that the likelihood of …

medicine.medical_specialtyCardiac troponincardiaccardiac troponin percutaneous coronary interventionmedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineMyocardial infarctionEvidence-Based Medicinebiologybusiness.industryReproducibility of ResultsPercutaneous coronary interventionGeneral MedicineEvidence-based medicinemedicine.diseaseTroponinTroponinTreatment OutcomePredictive value of testsConventional PCIbiology.proteinCardiologyMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of Cardiovascular Medicine
researchProduct

BMP-2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials.

2012

Objectives Combination of scaffolds and growth factors is a promising option for several clinical problems in bone biomaterials. Simplified growth factor loading by adsorption from aqueous solution is one important option for this technology. We evaluated the adsorption followed by PBS rinsing, release and biological effect of transient loading with basic fibroblast growth factor (bFGF) and bone morphogenic protein 2 (BMP-2) on fresh frozen bone, processed bone matrix, collagen, and a ceramic material with immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and qRT-PCR. Materials and methods The study consisted of three in vitro experiments (immunofluorescence, ELISA, and qRT-PCR…

medicine.medical_specialtyCeramicsTime Factorsmedicine.medical_treatmentBasic fibroblast growth factorOsteocalcinCell Culture TechniquesBone MatrixBone Morphogenetic Protein 2Fluorescent Antibody TechniqueBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitEnzyme-Linked Immunosorbent AssayBone healingMatrix (biology)Bone morphogenetic proteinBone morphogenetic protein 2Bone and Boneschemistry.chemical_compoundmedicineAnimalsHumansCells CulturedOsteoblastsbiologyTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionGrowth factorOsteoblastAlkaline PhosphataseSurgerymedicine.anatomical_structureDurapatitechemistryDelayed-Action PreparationsOsteocalcinbiology.proteinBiophysicsNanoparticlesFibroblast Growth Factor 2AdsorptionCollagenOral SurgeryBiomarkersClinical oral implants research
researchProduct

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

2020

Background & Aims The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection of early-stage HCC in patients with NASH have limitations. We assessed the ability of the GALAD score, which determines risk of HCC based on patient sex; age; and serum levels of α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. Methods We performed a case-control study of 125 patients with HCC (20% within Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD …

medicine.medical_specialtyCirrhosisCarcinoma HepatocellularMedizinPilot ProjectsMilan criteriaGastroenterologySensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineBiomarkers TumorHumansProtein PrecursorsneoplasmsHepatologyReceiver operating characteristicbusiness.industryLiver NeoplasmsGastroenterologyArea under the curvemedicine.diseasedigestive system diseasesROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaCase-Control StudiesCohort030211 gastroenterology & hepatologyProthrombinalpha-FetoproteinsbusinessLiver cancerBiomarkersCohort study
researchProduct

Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature.

2016

NAFLD (Non-Alcoholic Fatty Liver Disease) is an increasingly significant public health issue, regarded as the most relevant liver disease of the twenty-first century. Approximately 20%-30% of NAFLD subjects develop a NASH (Non-Alcoholic Steato-Hepatitis), a condition which can potentially evolve to liver cirrhosis and hepatocellular carcinoma. For these reasons a proper evaluation of liver damage is a key point for diagnosis and prognosis and liver biopsy still remains the "gold standard" procedure both for discrimination between steatosis and steatohepatitis and assessment of the degree of liver fibrosis. Nonetheless, given it is an invasive, painful and costly procedure, a great research …

medicine.medical_specialtyCirrhosisFibrosiBiopsyClinical Decision-MakingApoptosis030204 cardiovascular system & hematologyBiochemistryGastroenterologyMultimodal Imaging03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineAnimalsHumansMortalityMolecular BiologyLiver injurymedicine.diagnostic_testAnimalbusiness.industryFatty liverApoptosiBiomarkerGeneral Medicinemedicine.diseasePrognosisFibrosisdigestive system diseasesAlgorithmLiverLiver biopsyHepatocellular carcinomaMolecular Medicine030211 gastroenterology & hepatologySteatosisSteatohepatitisMorbiditybusinessAlgorithmsBiomarkersHumanCurrent molecular medicine
researchProduct

The Role of Imaging Biomarkers in the Assessment of Sarcopenia

2020

Background: The diagnosis of sarcopenia through clinical assessment has some limitations. The literature advises studies that include objective markers along with clinical assessment in order to improve the sensitivity and specificity of current diagnostic criteria. The decrease of muscle quality precedes the loss of quantity, so we studied the role magnetic resonance imaging biomarkers as indicators of the quantity and quality of muscle in sarcopenia patients. Methods: a cross-sectional analysis was performed to analyze what MR-derived imaging parameters correlate better with sarcopenia diagnostic criteria in women of 70 years of age and over (independent walking and community-dwelling wom…

medicine.medical_specialtyClinical BiochemistryMuscle massArticle030218 nuclear medicine & medical imagingFat massIndependent walkingsarcopeniaolder people03 medical and health sciences0302 clinical medicineInternal medicinemagnetic resonance imagingMedicineStage (cooking)lcsh:R5-920medicine.diagnostic_testbusiness.industryMagnetic resonance imagingmedicine.diseaseSpanish populationSarcopeniabiomarkerBiomarker (medicine)sarcopenia; magnetic resonance imaging; biomarker; older peoplelcsh:Medicine (General)businesshuman activities030217 neurology & neurosurgeryDiagnostics
researchProduct

A new tool for sepsis screening in the Emergency Department

2021

Abstract Objectives In this study, we developed and evaluated the diagnostic accuracy of the Sepsis Index for early sepsis screening in the Emergency Department (ED). Methods Sepsis Index is based on the combination of monocyte distribution width (MDW) and mean monocyte volume (MMV). Sepsis Index≥1 was selected to define sepsis. We tested its diagnostic accuracy in an ED population stratified in four groups: controls, Systemic Inflammatory Response Syndrome (SIRS), infection, and sepsis, according to Sepsis-2 criteria. Results Patients with sepsis displayed higher median Sepsis Index value than patients without sepsis. At the receiver operating characterictis (ROC) curve analysis for the pr…

medicine.medical_specialtyClinical BiochemistryPopulationDiagnostic accuracyGastroenterologyMonocytesSepsisSepsisInternal medicineHumansMedicineeducationeducation.field_of_studybusiness.industryBiochemistry (medical)Curve analysisArea under the curvemonocyte distribution width (MDW)Emergency DepartmentGeneral MedicineEmergency departmentPrognosismedicine.diseaseSystemic inflammatory response syndromeROC CurveArea Under CurvebiomarkerBiomarker (medicine)mean monocyte volume (MMV)Emergency Service HospitalbusinessBiomarkersClinical Chemistry and Laboratory Medicine (CCLM)
researchProduct

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

2020

Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…

medicine.medical_specialtyClinical Trials and Observationsmedicine.medical_treatmentMedizinADAMTS13 Protein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicinehemic and lymphatic diseasesvon Willebrand FactormedicineHumansIn patientRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpurabiologyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain AntibodiesADAMTS13Cardiovascular and Metabolic Diseases030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Caplacizumabbusiness
researchProduct

A methodological framework to enhance the clinical success of cancer immunotherapy.

2011

medicine.medical_specialtyClinical Trials as Topicbusiness.industrymedicine.medical_treatmentPublicationsBiomedical EngineeringBioengineeringGuidelines as TopicApplied Microbiology and BiotechnologyClinical successSurvival AnalysisText miningTreatment OutcomeCancer immunotherapyNeoplasmsBiomarkers TumorMolecular MedicineMedicineHumansMedical physicsCTLA-4 AntigenImmunotherapybusinessBiotechnologyNature biotechnology
researchProduct

New prognostic markers in neuroblastoma

2013

Introduction: The hallmark of neuroblastoma is its clinical and biological heterogeneity, with the likelihood of cure varying widely according to age at diagnosis, extent of disease and tumor biology. We hope this review will be useful for understanding part of the unfamiliar neuroblastoma codex. Areas covered: In the first part of this review, the authors summarize the currently used prognostic factors for risk-adapted therapy, with the focus on clinical management of neuroblastoma patients. In the second part, the authors discuss the evolving prognostic factors for future treatment schemes. A search of online medical research databases was undertaken focusing especially on literature publ…

medicine.medical_specialtyClinical variablesbusiness.industryTumor biologyBiochemistry (medical)Biomedical EngineeringAge at diagnosisExtent of diseaseGeneral MedicineBioinformaticsMedical researchmedicine.diseaseNeuroblastomaMolecular targetsMolecular MedicineMedicineBiomarker (medicine)businessIntensive care medicineExpert Opinion on Medical Diagnostics
researchProduct